- Report
- March 2025
- 175 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- March 2025
- 250 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- January 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- January 2025
- 124 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- May 2024
- 138 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- July 2024
- 150 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Clinical Trials
- June 2024
- 450 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Drug Pipelines
- April 2024
- 200 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Drug Pipelines
- April 2024
- 80 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Drug Pipelines
- April 2024
- 90 Pages
Global
From €1426EUR$1,500USD£1,198GBP
- Clinical Trials
- March 2025
- 60 Pages
Global
From €1426EUR$1,500USD£1,198GBP

Programmed Cell Death Protein (PDP) is a type of protein that plays a role in the regulation of cell death in the body. It is a key component of the body's natural defense against cancer, as it helps to prevent the growth and spread of cancerous cells. In oncology drugs, PDP is used to target and destroy cancer cells, while leaving healthy cells unharmed. PDP is also used to reduce the side effects of chemotherapy and radiation therapy, as well as to reduce the risk of recurrence of cancer. PDP is also used to reduce the risk of metastasis, or the spread of cancer to other parts of the body.
PDP is a rapidly growing market, with many companies developing and marketing PDP-based drugs. Some of these companies include Merck, Bristol-Myers Squibb, AstraZeneca, Novartis, and Pfizer. Show Less Read more